Repression of MAL tumour suppressor activity by promoter methylation during cervical carcinogenesis

Journal of Pathology

Volumn 219, Issue 3, 2009, Pages 327-336

  Overmeer, Renée M ^a   Henken, Florianne E ^a   Bierkens, Mariska ^a   Wilting, Saskia M ^a   Timmerman, Ilse ^a   Meijer, Chris J L M ^a   Snijders, Peter J F ^a   Steenbergen, Renske D M ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

AdCA; Cervical cancer; Gene silencing; MAL; Promoter methylation; Quantitative MSP; SCC

Indexed keywords

MESSENGER RNA; PROTEIN MAL; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

ANCHORAGE INDEPENDENT GROWTH; ARTICLE; CANCER RISK; CARCINOGENESIS; CELL IMMORTALIZATION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; KERATINOCYTE; METHYLATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RISK ASSESSMENT; UPREGULATION; UTERINE CERVIX BIOPSY; UTERINE CERVIX CANCER;

CELL LINE; CELL MOVEMENT; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; CELL TRANSFORMATION, VIRAL; DNA METHYLATION; DNA, NEOPLASM; FEMALE; GENE SILENCING; HUMANS; KERATINOCYTES; MEMBRANE TRANSPORT PROTEINS; MYELIN PROTEINS; NEOPLASM PROTEINS; PAPILLOMAVIRIDAE; PROMOTER REGIONS, GENETIC; PROTEOLIPIDS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, NEOPLASM; TUMOR CELLS, CULTURED; UTERINE CERVICAL NEOPLASMS;

EID: 70350443290     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.2598     Document Type: Article

References (35)

1. Walboomers JMM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999;189:12-19. (Pubitemid 29406813)
2. zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nature Rev Cancer 2002;2:342-350. (Pubitemid 37328947)
3. Richart RM. Causes and management of cervical intraepithelial neoplasia. Cancer 1987;60:1951-1959. (Pubitemid 17145914)
4. Solomon D, Davey D, Kurman R, Moriary A, O'Connor D, Prey M, et al. The 2001 Bethesda System - terminology for reporting results of cervical cytology. J Am Med Assoc 2002;287:2114-2119.
5. Snijders PJ, Steenbergen RD, Heideman DA, Meijer CJ. HPV-mediated cervical carcinogenesis: concepts and clinical implications. J Pathol 2006;208:152-164. (Pubitemid 43126109)
6. Steenbergen RD, Kramer D, Braakhuis BJ, Stern PL, Verheijen RH, Meijer CJ, et al. TSLC1 gene silencing in cervical cancer cell lines and cervical neoplasia. J Natl Cancer Inst 2004;96:294-305. (Pubitemid 38256274)
7. Wilting S, Snijders P, Meijer G, Ylstra B, van den Ijssel, Snijders A, et al. Increased gene copy numbers at chromosome 20q are frequent in both squamous cell carcinomas and adenocarcinomas of the cervix. J Pathol 2006;209:220-230. (Pubitemid 43805418)
8. Wilting SM, de Wilde J, Meijer CJ, Berkhof J, Yi Y, van Wieringen WN, et al. Integrated genomic and transcriptional profiling identifies chromosomal loci with altered gene expression in cervical cancer. Genes Chromosomes Cancer 2008;47:890-905.
9. Martin-Belmonte F, Puertollano R, Millan J, Alonso MA. The MAL proteolipid is necessary for the overall apical delivery of membrane proteins in the polarized epithelial Madin-Darby canine kidney and Fischer rat thyroid cell lines. Mol Biol Cell 2000;11:2033-2045. (Pubitemid 30408062)
10. Martin-Belmonte F, Arvan P, Alonso MA. MAL mediates apical transport of secretory proteins in polarized epithelial Madin-Darby canine kidney cells. J Biol Chem 2001;276:49337-49342. (Pubitemid 37370645)
11. Alonso MA, Barton DE, Francke U. Assignment of the T-cell differentiation gene MAL to human chromosome 2, region cen →q13. Immunogenetics 1988;27:91-95. (Pubitemid 18013497)
12. Steenbergen RDM, Walboomers JMM, Meijer CJLM, vander Raaij-Helmer EMH, Parker JN, Chow LT, et al. Transition of human papillomavirus type 16 and 18 transfected human foreskin keratinocytes towards immortality: activation of telomerase and allele losses at 3p, 10p, 11q and/or 18q. Oncogene 1996;13:1249-1257.
13. Hesselink AT, Bulkmans NW, Berkhof J, Lorincz AT, Meijer CJ, Snijders PJ. Cross-sectional comparison of an automated hybrid capture 2 assay and the consensus GP5+/6+ PCR method in a population-based cervical screening program. J Clin Microbiol 2006;44:3680-3685. (Pubitemid 46768821)
14. Meijer CJ, Berkhof J, Castle PE, Hesselink AT, Franco EL, Ronco G, et al. Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older. Int J Cancer 2009;124:516-520.
15. Bulkmans NW, Rozendaal L, Snijders PJ, Voorhorst FJ, Boeke AJ, Zandwijken GR, et al. POBASCAM, a population-based randomized controlled trial for implementation of high-risk HPV testing in cervical screening: design, methods and baseline data of 44,102 women. Int J Cancer 2004;110:94-101. (Pubitemid 38507208)
16. Bulkmans NW, Berkhof J, Rozendaal L, van Kemenade FJ, Boeke AJ, Bulk S, et al. Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial. Lancet 2007;370:1764-1772. (Pubitemid 350137476)
17. Jacobs MV, Snijders PJF, vanden Brule AJC, Helmerhorst TJM, Meijer CJLM, Walboomers JMM. A general primer GP5+/GP6+-mediated PCR-enzyme immunoassay method for rapid detection of 14 high-risk and 6 low-risk human papillomavirus genotypes in cervical scrapings. J Clin Microbiol 1997;35:791-795.
18. van den Brule AJ, Pol R, Fransen-Daalmeijer N, Schouls LM, Meijer CJ, Snijders PJ. GP5+/6+ PCR followed by reverse line blot analysis enables rapid and high-throughput identification of human papillomavirus genotypes. J Clin Microbiol 2002;40:779-787. (Pubitemid 34208623)
19. Buffart TE, Overmeer RM, Steenbergen RD, Tijssen M, van Grieken NC, Snijders PJ, et al. MAL promoter hypermethylation as a novel prognostic marker in gastric cancer. Br J Cancer 2008;99:1802-1807.
20. Harden SV, Guo Z, Epstein JI, Sidransky D. Quantitative GSTP1 methylation clearly distinguishes benign prostatic tissue and limited prostate adenocarcinoma. J Urol 2003;169:1138-1142. (Pubitemid 36188189)
21. Eads CA, Danenberg KD, Kawakami K, Saltz LB, Blake C, Shibata D, et al. MethyLight: a high-throughput assay to measure DNA methylation. Nucleic Acids Res 2000;28:E32.
22. Wisman GB, Nijhuis ER, Hoque MO, Reesink-Peters N, Koning AJ, Volders HH, et al. Assessment of gene promoter hypermethylation for detection of cervical neoplasia. Int J Cancer 2006;119:1908-1914. (Pubitemid 44356850)
23. Steenbergen RD, Parker JN, Isern S, Snijders PJ, Walboomers JM, Meijer CJ, et al. Viral E6-E7 transcription in the basal layer of organotypic cultures without apparent p21cip1 protein precedes immortalization of human papillomavirus type 16- and 18-transfected human keratinocytes. J Virol 1998;72:749-757. (Pubitemid 28048895)
24. Mimori K, Shiraishi T, Mashino K, Sonoda H, Yamashita K, Yoshinaga K, et al. MAL gene expression in esophageal cancer suppresses motility, invasion and tumorigenicity and enhances apoptosis through the Fas pathway. Oncogene 2003;22:3463-3471. (Pubitemid 36713744)
25. Hougardy BM, Maduro JH, van der Zee AG, de Groot DJ, van den Heuvel FA, de Vries EG, et al. Proteasome inhibitor MG132 sensitizes HPV-positive human cervical cancer cells to rhTRAIL-induced apoptosis. Int J Cancer 2006;118:1892-1900.
26. Puertollano R, Alonso MA. MAL, an integral element of the apical sorting machinery, is an itinerant protein that cycles between the trans-Golgi network and the plasma membrane. Mol Biol Cell 1999;10:3435-3447. (Pubitemid 29489573)
27. Hatta M, Nagai H, Okino K, Onda M, Yoneyama K, Ohta Y, et al. Down-regulation of members of glycolipid-enriched membrane raft gene family, MAL and BENE, in cervical squamous cell cancers. J Obstet Gynaecol Res 2004;30:53-58. (Pubitemid 38405064)
28. Horne HN, Lee PS, Murphy SK, Alonso MA, Olson JA Jr, Marks JR. Inactivation of the MAL gene in breast cancer is a common event that predicts benefit from adjuvant chemotherapy. Mol Cancer Res 2009;7:199-209.
29. Mimori K, Nishida K, Nakamura Y, Ieta K, Yoshikawa Y, Sasaki A, et al. Loss of MAL expression in precancerous lesions of the esophagus. Ann Surg Oncol 2007;14:1670-1677. (Pubitemid 46790982)
30. Henken FE, Wilting SM, Overmeer RM, van Rietschoten JG, Nygren AO, Errami A, et al. Sequential gene promoter methylation during HPV-induced cervical carcinogenesis. Br J Cancer 2007;97:1457-1464. (Pubitemid 350114795)
31. Wentzensen N, Sherman ME, Schiffman M, Wang SS. Utility of methylation markers in cervical cancer early detection: appraisal of the state-of-the-science. Gynecol Oncol 2009;112:293-299.
32. Overmeer R, Henken F, Snijders P, Claassen-Kramer D, Berkhof J, Helmerhorst T, et al. Association between dense CADM1 promoter methylation and reduced protein expression in high-grade CIN and cervical SCC. J Pathol 2008;215:388-397.
33. Bulk S, Visser O, Rozendaal L, Verheijen RH, Meijer CJ. Cervical cancer in The Netherlands, 1989-1998: decrease of squamous cell carcinoma in older women, increase of adenocarcinoma in younger women. Int J Cancer 2005;113:1005-1009.
34. Smith HO, Tiffany MF, Qualls CR, Key CR. The rising incidence of adenocarcinoma relative to squamous cell carcinoma of the uterine cervix in the United States - a 24-year population-based study. Gynecol Oncol 2000;78:97-105.
35. Vizcaino AP, Moreno V, Bosch FX, Munoz N, Barros-Dios XM, Parkin DM. International trends in the incidence of cervical cancer: I. Adenocarcinoma and adenosquamous cell carcinomas. Int J Cancer 1998;75:536-545. (Pubitemid 28094098)